AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ECO ANIMAL HEALTH GROUP PLC

Share Issue/Capital Change Dec 18, 2025

7612_rns_2025-12-18_2173e49e-ebcb-468e-a6b6-2a94cafbf0db.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 0209M

Eco Animal Health Group PLC

18 December 2025

18 December 2025

ECO Animal Health Group plc

("ECO" or the "Company")

Exercise of Share Options and Director/PDMR Shareholdings

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that Christopher Wilks, Chief Financial Officer, has exercised 4,309 nominal cost share options granted under the Company's Deferred Bonus Share Options scheme (the "Scheme"). These share options were granted on 12 December 2022 as a deferral of one-third of Mr Wilks' bonus relating to the year ended 31 March 2022.

The exercise has been fully satisfied through the transfer of existing ordinary shares held by the ECO Animal Health Group Employee Benefit Trust ("EBT"). No new ordinary shares have been issued in connection with this transaction.

As a result of this transaction, Mr. Wilks' total beneficial shareholding in the Company is now 178,186 ordinary shares, representing approximately 0.26% of the Company's issued share capital ("ISC").

Therefore, the total number of ordinary shares with voting rights in the Company remains at 67,759,671. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Group under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The notifications below, provided in accordance with the requirements of the UK Market Abuse Regulation, provide further details

-Ends-

For further information please contact:

ECO Animal Health Group plc

David Hallas (Chief Executive Officer)

Christopher Wilks (Chief Financial Officer)
020 8447 8899
ICR Healthcare (Financial PR)

Mary-Jane Elliott

Jessica Hodgson
020 3709 5700
Singer Capital Markets (Nominated Adviser & Joint Broker)

Philip Davies

Samed Ethemi
020 7496 3000
Panmure Liberum (Joint Broker)

Emma Earl

Will Goode

Mark Rogers

Rupert Dearden
020 3100 2000
Equity Development

Hannah Crowe

Matt Evans
020 7065 2692

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

PDMR Notification - ECO LTIP Nominal Cost Conditional Share Awards

1.           

Details of the person discharging managerial responsibilities / person closely associated

a.            

Name

Christopher Wilks           

2.            

Reason for the notification

a.            

Position/status

Chief Financial Officer

b.            

Initial notification

/Amendment

Initial notification

3.            

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.           

Name

Eco Animal Health Group Plc

b.           

LEI

2138009XN9DJ3YP7OB55

4.            

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.            

Description of the

Financial instrument, type of instrument

Identification code

Options over ordinary shares of 5p each.

GB0032036807 

b.            

Nature of the transaction

1.    Nominal cost share awards under the Company's Deferred Bonus Share Options ("DBS").

c.            

Price(s) and volume(s)

Price(s) Volume(s)
2. DBS 5p 4,309

d.            

Aggregated information

Aggregated volume

Price 

n/a

e.            

Date of the transaction

17 December 2025

f.            

Place of the transaction

Off Market

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCGZMMZLNKGKZM

Talk to a Data Expert

Have a question? We'll get back to you promptly.